• Logo
  • HamaraJournals

Investigation of Anti-Coronavirus, Anti-HCV, Nucleotide Inhibitors, and Bioactive Molecules efficacy Against RNA-directed RNA polymerase of Nipah Virus: Molecular Docking Study

Peter T. Habib
57

Views


Abstract

Introduction: The infections with the Nipah virus (NiV) are highly infectious and may lead to severe febrile encephalitis. High mortality rates in southeastern Asia, including Bengal, Malaysia, Papua New Guinea, Vietnam, Cambodia, Indonesia, Madagascar, the Philippines, Thailand, and India, have been reported in NiV outbreaks. Considering the high risk of an epidemic, NiV was declared a priority pathogen by the World Health Organization. However, for the treatment of this infection, there is no effective therapy or approved FDA medicines. RNA-dependent polymerase RNA (RdRp) plays an important role in viral replication among the nine well-known proteins of NiV.

Material and Methods: Fourteen antiviral molecules have been computerized for NiV RNA-dependent RNA polymerase and demonstrated a potential inhibition effect against coronavirus (NiV-RdRp). A multi-step molecular docking process, followed by extensive analyzes of molecular binding interactions, binding energy estimates, synthetic accessibility assessments, and toxicity tests.

Results: Molecular docking analysis reveals that Uprifosbuvir is the most suitable inhibitor for RdRp of Nipah Virus regarding the binding affinity and binding in the target cavity. Although, such studies need clinical confirmation.

Conclusion: The role of anti-viral molecules as a ligand against RNA-dependent RNA polymerase is critical important in the current era. Computational tools such as molecular docking has proven its power in the analysis of molecules interaction. Our analysis reveals the Uprifosbuvir might be a candidate RdRp inhibitor. This study should further investigate the properties of the already identified anti-viral molecules followed by a pharmacological investigation of these in-silico findings in suitable models.

References

Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: A recently emergent deadly paramyxovirus. Science. 2000; 288(5470): 1432–5. PMID: 10827955 DOI: 10.1126/science.288.5470.1432

Chattu VK, Kumar R, Kumary S, Kajal F, David JK. Nipah virus epidemic in southern India and emphasizing “One Health” approach to ensure global health security. J Family Med Prim Care. 2018; 7(2): 275-83. PMID: 30090764 DOI: 10.4103/jfmpc.jfmpc_137_18

Olson JG, Rupprecht C, Rollin PE, An US, Niezgoda M, Clemins T, et al. Antibodies to Nipah-like virus in bats (Pteropus lylei), Cambodia. Emerg Infect Dis. 2002; 8(9): 987-8. PMID: 12194780 DOI: 10.3201/eid0809.010515

Luby SP. The pandemic potential of Nipah virus. Antiviral Res. 2013; 100(1): 38-43. PMID: 23911335 DOI: 10.1016/j.antiviral.2013.07.011

Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J Gen Virol. 2010; 91(Pt 3): 765-72. PMID: 19889926 DOI: 10.1099/vir.0.017269-0

Tigabu B, Rasmussen L, White EL, Tower N, Saeed M, Bukreyev A, et al. A BSL-4 high-throughput screen identifies sulfonamide inhibitors of Nipah virus. Assay Drug Dev Technol. 2014; 12(3): 155–61. PMID: 24735442 DOI: 10.1089/adt.2013.567

Niedermeier S, Singethan K, Rohrer SG, Matz M, Kossner M, Diederich S, et al. A small-molecule inhibitor of Nipah virus envelope protein-mediated membrane fusion. J Med Chem. 2009; 52(14): 4257–65. PMID: 19499921 DOI: 10.1021/jm900411s

Dawes BE, Kalveram B, Ikegami T, Juelich T, Smith JK, Zhang L, et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 2018; 8(1): 7604. PMID: 29765101 DOI: 10.1038/s41598-018-25780-3

Hotard AL, He B, Nichol ST, Spiropoulou CF, Lo MK. 4′-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency. Antiviral Res. 2017; 144: 147–52. PMID: 28629988 DOI: 10.1016/j.antiviral.2017.06.011

Snell NJC. Ribavirin therapy for Nipah virus infection. J Virol. 2004; 78(18): 10211. PMID: 15331756 DOI: 10.1128/JVI.78.18.10211.2004

Chong H-T, Kamarulzaman A, Tan C-T, Goh K-J, Thayaparan T, Kunjapan SR, et al. Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol. 2001; 49(6): 810-3. PMID: 11409437 DOI: 10.1002/ana.1062

Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MCG, Deubel V, et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol. 2006; 80(4): 1972–8. PMID: 16439553 DOI: 10.1128/JVI.80.4.1972-1978.2006

Habib PT. Vaccine design, adaptation, and cloning design for multiple epitope-based vaccine derived from SARS-CoV-2 surface glycoprotein (S), membrane protein (M) and envelope protein (E): In silico approach. Front Health Inform. 2021; 10: 67.

Habib PT, Saber-Ayad M, Hassanein SE. In silico analysis of 716 natural bioactive molecules form Atlantic ocean reveals candidate molecule to inhibit spike protein [Internet]. 2021 [cited: 2021 Mar 3]. Available from: https://www.researchsquare.com/article/rs-156623/v1

Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: A powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011; 7(2): 146-57. PMID: 21534921 DOI: 10.2174/157340911795677602

Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004; 3(8): 711-5. PMID: 15286737 DOI: 10.1038/nrd1470

Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, et al. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chem MedChem. 2007; 2(6): 861-73. PMID: 17477341 DOI: 10.1002/cmdc.200700026

Brouwers L, Iskar M, Zeller G, van Noort V, Bork P. Network neighbors of drug targets contribute to drug side-effect similarity. PloS One. 2011; 6(7): e22187. PMID: 21765950 DOI: 10.1371/journal.pone.0022187

Habib PT, Alsamman AM, Saber-Ayad M, Hassanein SE, Hamwieh A. COVIDier: A deep-learning tool for coronaviruses genome and virulence proteins classification [Internet]. 2020 [cited: 2021 Mar 3]. Available from: https://www.biorxiv.org/content/10.1101/2020.05.03.075549v1.abstract

Habib PT. COVATOR: A Software for chimeric coronavirus identification [Internet]. 2020 [cited: 2021 Mar 3]. Available from: https://www.biorxiv.org/content/10.1101/2020.11.14.383075v1.abstract

Habib PT, Alsamman AM, Hassanein SE, Hamwieh A. Developing convolutional neural networks-based system for predicting pneumonia using X-radiography image. Highlights in BioScience. 2020; 3: 1-3.

Noh H, Shoemaker JE, Gunawan R. Network perturbation analysis of gene transcriptional profiles reveals protein targets and mechanism of action of drugs and influenza: A viral infection. Nucleic Acids Res. 2018; 46(6): e34. PMID: 29325153 DOI: 10.1093/nar/gkx1314

Habib PT. Learning from COVID-19 pandemic: In silico vaccine and cloning design against Nipah virus by studying and analyzing the whole Nipah virus proteome [Internet]. 2021 [cited: 2021 Mar 3]. Available from: https://www.researchsquare.com/article/rs-269666/v1

Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: Modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014; 42(Web Server Issue): W252-8. PMID: 24782522 DOI: 10.1093/nar/gku340




DOI: http://dx.doi.org/10.30699/fhi.v10i1.288

Refbacks

  • There are currently no refbacks.